Benazepril: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
No edit summary |
||
| (8 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='340' side='right' caption='Benazepril, also known as Lotensin' scene='Benazepril/Benazepril/1'> | ||
===Better Known as: Lotensin=== | ===Better Known as: Lotensin (Lotrel when combined with Amlodipine)=== | ||
* Marketed By: Novartis International AG<br /> | * Marketed By: Novartis International AG<br /> | ||
* Major Indication: Hypertension & Congestive Heart Failure<br /> | * Major Indication: [[Hypertension & Congestive Heart Failure]]<br /> | ||
* Drug Class: [[ACE]] Inhibitor | * Drug Class: [[ACE]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): 1991 (2003)<br /> | * Date of FDA Approval (Patent Expiration): 1991 (2003)<br /> | ||
* 2002 Sales: $300 Million | * 2002 Sales (Lotrel 2005 Sales): $300 Million ($1.2 Billion) | ||
* | * Importance: One of the earliest and best selling [[Angiotensin-Converting Enzyme]] Inhibitors of all time. | ||
* | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
===Mechanism of Action=== | ===Mechanism of Action=== | ||
Angiotensin II has been implicated in cardiac, renal and vascular diseases. <ref>PMID:17083068</ref> Bradykinin, a small peptide that counterbalance the effects of Angiotensin II by acting as a strong vasodilator upon binding AT2, is degraded by the same ACE-1 enzyme. Since ACE-1 is the primary producer of Angiotensin II and degrader of Bradykinins, inhibition of ACE-1 has proven an effective treatment for Hypertension and Congestive Heart Failure | Angiotensin II has been implicated in cardiac, renal and vascular diseases. <ref>PMID:17083068</ref> Bradykinin, a small peptide that counterbalance the effects of Angiotensin II by acting as a strong vasodilator upon binding AT2, is degraded by the same ACE-1 enzyme. Since [[ACE|ACE-1]] is the primary producer of Angiotensin II and degrader of Bradykinins, inhibition of ACE-1 has proven an effective treatment for Hypertension and Congestive Heart Failure.<ref>PMID:15236580</ref> | ||
</StructureSection> | |||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | |||
<tr> | |||
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset"> | |||
<div style="height:100%; width: 100%"> | |||
{{:ACE Inhibitor Pharmacokinetics}} | |||
</div> | |||
</td> | |||
</tr> | |||
</table> | |||
==References== | ==References== | ||
